These MALTs possess unique functional characteristics, including antigen sampling by M cells and subsequent processing and presentation by antigen-presenting cells
, resulting in the initiation of antigen-specific mucosal immune responses.
The deliberations start when T cells and antigen-presenting cells
meet in the lymph nodes, causing a series of molecular events leading to the activation of a protein called Ras.
Firstly by targeting antigen-presenting cells
we get a faster and longer lasting immune response at a lower dose that traditional vaccines.
In addition to getting instructions from the antigen-presenting cells
, CD8 T cells need assistance from helper T cells to become effective killers.
In the presence of minute amounts of the antigen, immune responsibility gradually shifts back to the more friendly reception of T cells and antigen-presenting cells
Sipuleucel-T would be the first oncologic drug in a new class, designed to stimulate a patient's immune system with a "vaccine" made from his own peripheral blood mononuclear cells, including antigen-presenting cells
We have evidence that ethylmercury and thimerosal alter the signaling properties of antigen-presenting cells
, known as dendritic cells, at nanomolar levels.
The Ii protein normally blocks the antigenic peptide binding site of MHC Class II molecules at time of synthesis in the endoplasmic reticulum of antigen-presenting cells
United States patent 6,429,199 entitled "Immunostimulatory nucleic acid molecules for activating dendritic cells" relates to the use of CpG oligos which have a specific nucleotide sequence, including at least one unmethylated CpG dinucleotide, to stimulate potent antigen-presenting cells
The second study was titled "Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
(APCs)" (Basha et al.
Apexigen's APX005M is a novel, humanized monoclonal CD40 agonist antibody that stimulates the anti-tumor immune response in the tumor microenvironment through activation of antigen-presenting cells
of the immune system.
According to the company, the new allowed patent application joins the patent US 8,026,223, which claims a method of treating cancerous tumors with plasmid-encoded IL-12 and electroporation therapy to the tumor; and patent US 8,802,643, which claims a method of treating cancerous tumors with plasmid-encoded B7-1, a peripheral membrane protein found on antigen-presenting cells
(APCs) and electroporation therapy to the tumor, both of which have a field strength of at least 700 V/cm.